CORDIS
EU research results

CORDIS

English EN

In Silico Trial for Tuberculosis Vaccine Development

Project information

Grant agreement ID: 777123

Status

Ongoing project

  • Start date

    1 February 2018

  • End date

    31 July 2022

Funded under:

H2020-EU.3.1.5.

  • Overall budget:

    € 5 050 656,25

  • EU contribution

    € 4 549 527,50

Coordinated by:

ETNA BIOTECH SRL

Italy

Objective

Tuberculosis (TB) one of the world’s deadliest diseases: one third of the world’s population, mostly in developing countries, is infected with TB. But TB is becoming again very dangerous also for developed countries, due to the increased mobility of the world population, and the appearance of several new bacterial strains that are multi-drug resistant (MDR). There is now a growing awareness that TB can be effectively fought only working globally, starting from countries like India, where the infection is endemic. Once a person present the active disease, the most critical issue is the current duration of the therapy, because of the high costs it involved, the increased chances of non-compliance (which increase the probability of developing an MDR strain), and the time the patient is still infectious to others. One exciting possibility to shorten the duration of the therapy are new host-reaction therapies (HRT) as a coadjuvant of the antibiotic therapy. The endpoints in the clinical trials for HRTs are time to inactivation, and incidence of recurrence. While for the first it is in some cases possible to have a statistically powered evidence for efficacy in a phase II clinical trial, recurrence almost always require a phase III clinical trial with thousands of patients involved, and huge costs. In the STriTuVaD project we will extend our Universal Immune System Simulator to include all relevant determinants of such clinical trial, establish its predictive accuracy against the individual patients recruited in the trial, use it to generate virtual patients and predict their response to the HRT being tested, and combine them to the observations made on physical patients using a new in silico-augmented clinical trial approach that uses a Bayesian adaptive design. This approach, where found effective could drastically reduce the cost of innovation in this critical sector of public healthcare.

Coordinator

ETNA BIOTECH SRL

Address

Strada Vincenzo Lancia 57
95100 Catania

Italy

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 043 750

Participants (7)

UNIVERSITA DEGLI STUDI DI CATANIA

Italy

EU Contribution

€ 909 393,75

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 465 323,75

ARCHIVEL FARMA, SL

Spain

EU Contribution

€ 408 360

STICHTING TUBERCULOSIS VACCINE INITIATIVE

Netherlands

EU Contribution

€ 65 625

INFECTIOUS DISEASE RESEARCH INSTITUTE

United States

EU Contribution

€ 1 255 027,50

THE ALL-INDIA INSTITUTE OF MEDICAL SCIENCES

India

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA

Italy

EU Contribution

€ 402 047,50

Project information

Grant agreement ID: 777123

Status

Ongoing project

  • Start date

    1 February 2018

  • End date

    31 July 2022

Funded under:

H2020-EU.3.1.5.

  • Overall budget:

    € 5 050 656,25

  • EU contribution

    € 4 549 527,50

Coordinated by:

ETNA BIOTECH SRL

Italy